Literature DB >> 32682508

Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer.

Michael D Bortz1, Kristine Kuchta2, David J Winchester2, Richard A Prinz2, Tricia A Moo-Young2.   

Abstract

BACKGROUND: The eighth edition American Joint Committee on Cancer tumor-node-metastasis staging for well-differentiated thyroid cancers, no longer considers "minimal" extrathyroidal extension for tumor staging. This change prompted us to examine the effect of extrathyroidal extension on patient outcomes.
METHODS: Patients (n = 177,497) in the 2016 National Cancer Database with classic papillary thyroid cancer were evaluated to determine the effect of extrathyroidal extension on overall survival and risk for nodal and distant metastases. Kaplan-Meier curves with the log-rank test were used to evaluate survival differences. Multivariable Cox and logistic regression analyses included relevant clinicopathologic variables (e.g. age, sex, race, and Charlson Comorbidity Index).
RESULTS: Patients with "minimal" extrathyroidal extension had worse survival versus patients with no extrathyroidal extension (10-year survival 89.3% vs 93.1%, hazard ratio 1.23; 95% confidence interval, 1.13-1.35; P < .001). Any extrathyroidal extension was associated with higher risks for lymph node (odds ratio 2.78; 95% confidence interval, 2.69-2.87) and distant metastasis (odds ratio 3.5; 95% confidence interval, 3.05-4.04). These associations persisted when comparing "micro" (extension into the thyroid capsule) versus none for nodal risk (odds ratio 1.25; 95% confidence interval, 1.18-1.33) and distant metastasis (OR 1.52; 95% confidence interval, 1.11-2.09).
CONCLUSION: All levels of extrathyroidal extension, including microscopic, were associated with increased risk for nodal and distant metastasis. Both minimal and macroscopic extrathyroidal extension were also associated with decreased overall survival. Such findings have the potential to affect the clinical decision making for patients diagnosed with papillary thyroid cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32682508     DOI: 10.1016/j.surg.2020.04.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Development of a Risk Predictive Model for Evaluating Immune Infiltration Status in Invasive Thyroid Carcinoma.

Authors:  Runming Pang; Chunxin Qin
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-03       Impact factor: 2.650

2.  Risk Factors for Central and Lateral Lymph Node Metastases in Patients With Papillary Thyroid Micro-Carcinoma: Retrospective Analysis on 484 Cases.

Authors:  Yijie Huang; Ying Yin; Wenyi Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-05       Impact factor: 5.555

3.  High Incidence of Distant Metastasis Is Associated With Histopathological Subtype of Pediatric Papillary Thyroid Cancer - a Retrospective Analysis Based on SEER.

Authors:  Xue Zeng; Zhihong Wang; Zhiqiang Gui; Jingzhe Xiang; Mengsu Cao; Wei Sun; Liang He; Wenwu Dong; Jiapeng Huang; Dalin Zhang; Chengzhou Lv; Ting Zhang; Liang Shao; Ping Zhang; Hao Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

4.  Microscopic Extrathyroidal Extension Results in Increased Rate of Tumor Recurrence and Is an Independent Predictor of Patient's Outcome in Middle Eastern Papillary Thyroid Carcinoma.

Authors:  Sandeep Kumar Parvathareddy; Abdul K Siraj; Zeeshan Qadri; Felisa DeVera; Khawar Siddiqui; Saif S Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

5.  The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication.

Authors:  Wei Peng; Wenqiang Li; Xiaoyong Zhang; Weili Cen; Yanan Liu
Journal:  J Clin Lab Anal       Date:  2022-07-15       Impact factor: 3.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.